Karen Zaderej's Insider Trades & SAST Disclosures
Karen Zaderej's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 5,000 Common Stock done at an average price of $5.4 . Disclosure was reported to the exchange on May 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Karen Zaderej.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 14 May 2025 | 5,000 | 21,500 (0%) | 0% | 5.4 | 27,100 | Common Stock |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 5.47 per share. | 14 May 2025 | 5,000 | 26,500 (0%) | 0% | 5.5 | 27,350 | Common Stock |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Purchase of securities on an exchange or from another person at price $ 7.98 per share. | 19 Aug 2024 | 12,500 | 16,500 (0%) | 0% | 8.0 | 99,750 | Common Stock |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 2,000 | 4,000 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 84,847 | 84,847 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 84,847 | 1,157,593 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 7.68 per share. | 16 Mar 2024 | 33,028 | 1,124,565 (2%) | 0% | 7.7 | 253,655 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,975 | 1,146,954 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,975 | 0 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,500 | 1,137,065 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2024 | 12,500 | 12,500 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 7.68 per share. | 16 Mar 2024 | 3,166 | 1,143,788 (2%) | 0% | 7.7 | 24,315 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 7.68 per share. | 16 Mar 2024 | 3,086 | 1,133,979 (2%) | 0% | 7.7 | 23,700 | Common Stock |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 2,000 | 2,000 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 179,000 | 179,000 | - | - | Employee Stock Option (right to purchase) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 112,000 | 112,000 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 25,000 | 1,037,695 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,975 | 1,050,670 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 12,975 | 12,975 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2022 | 4,400 | 1,012,695 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2022 | 4,400 | 0 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2022 | 26,746 | 0 | - | - | Employee Stock Option (right to buy) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.09 per share. | 15 Dec 2022 | 26,746 | 1,008,295 (2%) | 0% | 5.1 | 136,137 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 22,076 | 988,409 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale or transfer of securities back to the company at price $ 8.40 per share. | 18 Jul 2022 | 9,081 | 981,549 (2%) | 0% | 8.4 | 76,280 | Common Stock |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Karen Zaderej | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 317,185 | 317,185 | - | - | Employee Stock Option (right to purchase) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 169,694 | 169,694 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 25,950 | 25,950 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 25,950 | 966,333 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 13,978 | 940,383 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 4,400 | 4,400 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 4,400 | 927,429 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.74 per share. | 27 Dec 2021 | 1,752 | 925,677 (2%) | 0% | 9.7 | 17,064 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 3,125 | 0 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 3,125 | 924,272 (2%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.24 per share. | 20 Dec 2021 | 1,243 | 923,029 (2%) | 0% | 9.2 | 11,485 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.95 per share. | 24 Nov 2021 | 52,375 | 921,147 (2%) | 0% | 8.9 | 468,756 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2021 | 52,375 | 157,125 | - | - | Employee Stock Option (right to purchase) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 46,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 12 Aug 2021 | 46,500 | 868,772 (2%) | 0% | 3.7 | 170,655 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.09 per share. | 12 Aug 2021 | 8,254 | 822,272 (2%) | 0% | 5.1 | 42,013 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 8,254 | 26,746 | - | - | Employee Stock Option (right to buy) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 75,000 | 35,000 | - | - | Employee Stock Option (right to purchase) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.09 per share. | 06 Aug 2021 | 75,000 | 855,018 (2%) | 0% | 5.1 | 381,750 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.41 per share. | 06 Aug 2021 | 22,902 | 816,101 (2%) | 0% | 18.4 | 421,626 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.40 per share. | 06 Aug 2021 | 14,756 | 840,262 (2%) | 0% | 18.4 | 271,510 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 19.16 per share. | 06 Aug 2021 | 2,083 | 814,018 (2%) | 0% | 19.2 | 39,910 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 19.18 per share. | 06 Aug 2021 | 1,259 | 839,003 (2%) | 0% | 19.2 | 24,148 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 22,077 | 788,830 (1%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.20 per share. | 19 Jul 2021 | 8,812 | 780,018 (1%) | 0% | 19.2 | 169,190 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2021 | 100,000 | 110,000 | - | - | Employee Stock Option (right to purchase) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.09 per share. | 16 Apr 2021 | 100,000 | 765,912 (1%) | 0% | 5.1 | 509,000 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 25 Mar 2021 | 34,500 | 665,912 (1%) | 0% | 3.7 | 126,615 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 19,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 15,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 76,600 | 76,600 | - | - | Employee Stock Option (right to purchase) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 16,021 | 625,120 (1%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 13,978 | 634,916 (1%) | 0% | 0 | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.71 per share. | 16 Feb 2021 | 4,182 | 620,938 (1%) | 0% | 18.7 | 78,245 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.71 per share. | 16 Feb 2021 | 3,504 | 631,412 (1%) | 0% | 18.7 | 65,560 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 08 Jan 2021 | 65,000 | 609,099 (1%) | 0% | 20 | 1,300,000 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2020 | 8,800 | 677,599 (1%) | 0% | - | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 27 Dec 2020 | 3,500 | 674,099 (1%) | 0% | 17.8 | 62,335 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.81 per share. | 23 Dec 2020 | 19,375 | 666,094 (1%) | 0% | 4.8 | 93,194 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2020 | 19,375 | 0 | - | - | Employee Stock Option (right to buy) | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 3,125 | 647,994 (1%) | 0% | - | Common Stock | |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.42 per share. | 18 Dec 2020 | 1,275 | 646,719 (1%) | 0% | 16.4 | 20,936 | Common Stock |
| Axogen Inc. | Karen Zaderej | Director, CEO | Sale of securities on an exchange or to another person at price $ 14.53 per share. | 09 Nov 2020 | 14,000 | 644,869 (1%) | 0% | 14.5 | 203,420 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges